Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Ziv Hospital Merck |
---|---|
Information provided by: | Ziv Hospital |
ClinicalTrials.gov Identifier: | NCT00466401 |
The aim of our study is to Estimate the reduction of LDL by ezetimibe in hypercholesterolemic patients on simvastatin.Investigate the effect of LDL lowering by ezetimibe on platelet activity and LDL tendency to peroxidation in hypercholesterolemic patients on simvastatin therapy
The hypothesis is that:
Condition | Intervention | Phase |
---|---|---|
Hypercholesterolemia |
Drug: Simvastatin Drug: Ezetimibe |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment |
Official Title: | Phase 4 Study on Effect of Ezetimibe on Platelet Aggregation and LDL Tendency to Peroxidation In Hypercholesterolemic Patients on Simvastatin |
Estimated Enrollment: | 20 |
Study Start Date: | February 2005 |
Study Completion Date: | August 2007 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | HP-5-155-S |
Study First Received: | April 25, 2007 |
Last Updated: | August 13, 2007 |
ClinicalTrials.gov Identifier: | NCT00466401 |
Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
Metabolic Diseases Hyperlipidemias Simvastatin Ezetimibe |
Metabolic disorder Hypercholesterolemia Dyslipidemias Lipid Metabolism Disorders |
Antimetabolites Molecular Mechanisms of Pharmacological Action Therapeutic Uses Antilipemic Agents |
Enzyme Inhibitors Anticholesteremic Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Pharmacologic Actions |